These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20048722)

  • 1. Resistance to novel drug classes.
    Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
    Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
    Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
    Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
    Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C
    Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Integrase inhibitor, CCR5 antagonist, fusion inhibitor].
    Gatanaga H
    Nihon Rinsho; 2010 Mar; 68(3):520-4. PubMed ID: 20229801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mehanisms of drug resistance acquisition in HIV].
    Sugiura W
    Nihon Rinsho; 2009 Jan; 67(1):43-51. PubMed ID: 19177751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV type 1 coreceptor tropism, CCR5 genotype, and integrase inhibitor resistance profiles in Vietnam: implications for the introduction of new antiretroviral regimens.
    Luu QP; Dean J; Do TT; Carr MJ; Dunford L; Coughlan S; Connell J; Nguyen HT; Hall WW; Nguyen Thi LA
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1344-8. PubMed ID: 22264071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.